Madame Bioscience Public Company Limited

As of June 30, 2026, Madame Bioscience Public Company Limited NVDR carries a market capitalization of 403.90M, placing it among publicly traded companies globally. Its enterprise value stands at 538.23M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Madame Bioscience Public Company Limited NVDR has 807.81M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.25, and the price-to-book ratio stands at 0.50.

As of June 30, 2026, Madame Bioscience Public Company Limited NVDR trades at an EV/EBITDA multiple of 5.12 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.34 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 31.66 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 538.23M versus a market cap of 403.90M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Madame Bioscience Public Company Limited NVDR maintains a current ratio of 1.51, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.65, indicating elevated leverage, while an interest coverage ratio of 4.76 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Madame Bioscience Public Company Limited NVDR posted a negative return on equity (ROE) of -18.20, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.84, reflecting losses generated across the asset base. The company generates approximately 5.24M in revenue per employee across its workforce of 302.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 13.48 indicates how many times Madame Bioscience Public Company Limited NVDR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Madame Bioscience Public Company Limited NVDR recorded an income tax benefit of -10.48M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -152.36M and -141.06M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Madame Bioscience Public Company Limited NVDR's stock has gained approximately 6.32% over the past 52 weeks. The 50-day moving average sits at 1.04, while the 200-day moving average is 0.70.

Over the twelve months ended June 30, 2026, Madame Bioscience Public Company Limited NVDR generated 1.58B in revenue and converted that into -141.06M in net income, yielding earnings per share of -0.18. EBITDA reached 105.03M, while operating income came in at -43.22M.

As of June 30, 2026, Madame Bioscience Public Company Limited NVDR holds 127.51M in cash and equivalents against 218.08M in total debt, resulting in a net debt position of 79.65M. Total book value stands at 806.32M, with working capital of 142.61M providing operational flexibility.

Madame Bioscience Public Company Limited NVDR produced 37.35M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -52.89M in capital expenditures, free cash flow totaled -15.54M - equivalent to -0.02 per share.

Over the twelve months ended June 30, 2026, Madame Bioscience Public Company Limited NVDR posted a gross margin of 28.42, reflecting its pricing power and cost economics. The operating margin of -2.73 and net profit margin of -8.91 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Madame Bioscience Public Company Limited NVDR paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -3.96: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -19.44, meaning Madame Bioscience Public Company Limited NVDR raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Madame Bioscience Public Company Limited NVDR's most recent stock split took place on February 16, 2026 with a 5:1 split ratio.

As of June 30, 2026, Madame Bioscience Public Company Limited NVDR has an Altman Z-Score of 2.47, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.